Category: Gaucher disease

VPRIV (velaglucerase alfa) was approved by the U.S. Food and Drug Administration (FDA) in 2010 for long-term treatment of Type 1 Gaucher disease. For those asking what is the generic for VPRIV, it is important to understand that this medication, as a biologic, does not have a generic version in the traditional sense.

For patients with type 1 Gaucher disease, VPRIV is typically administered as a 60-minute intravenous infusion once every other week. However, the total time spent at an infusion center is often longer to account for patient assessment, medication preparation, and a crucial period of post-treatment monitoring by a healthcare professional.

Gaucher disease affects an estimated 1 in 50,000 to 100,000 people in the general population [1.10.4]. For those undergoing enzyme replacement therapy, a primary question is: **how long does a Cerezyme infusion take?** This intravenous treatment typically lasts between one to two hours [1.2.1, 1.2.2].

Approved by the FDA in 2010, Vpriv (velaglucerase alfa) has over a decade of real-world experience as a long-term enzyme replacement therapy (ERT). It is used to treat Type 1 Gaucher disease in adults and children ages 4 and older.

Affecting approximately 1 in 40,000 to 60,000 live births, Gaucher disease is a rare genetic disorder caused by a deficient enzyme called glucocerebrosidase. The **cerezyme treatment** is an enzyme replacement therapy designed to manage the symptoms of this serious condition.